NellOne Therapeutics, Inc.

NellOne Therapeutics is an early stage, regenerative medicine company developing protein therapeutics for restoring both cardiac muscle mass and function in patients recovering from myocardial infarction and congestive cardiac failure. Spun out of the U.S. Department of Energy’s Oak Ridge National Laboratory (ORNL), NellOne has demonstrated through independent studies the potential efficacy of the company’s lead therapeutic candidate for both skeletal muscle wound healing and heart attacks. The company’s technology platform is based on activity of the Nell1 gene's pathway in the formation of key mammalian tissues and organs identified by NellOne founder Dr. Cymbeline Culiat as a senior staff scientist at ORNL. NellOne has received exclusively licensed patents on inventions based on the Nell1 gene. General Partner Tracy Warren is CEO and a member of the Board of Directors. (See efficacy studies announcement.)

Company Web Site
www.nell-one.com